AR035400A1 - Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo - Google Patents
Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararloInfo
- Publication number
- AR035400A1 AR035400A1 ARP010105594A ARP010105594A AR035400A1 AR 035400 A1 AR035400 A1 AR 035400A1 AR P010105594 A ARP010105594 A AR P010105594A AR P010105594 A ARP010105594 A AR P010105594A AR 035400 A1 AR035400 A1 AR 035400A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- alkyl
- alkylsulfonyl
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describe un compuesto antagonista del receptor de adenosina A1, caracterizado por la fórmula (1): en donde R1 y R2 son seleccionados independientemente del grupo formado por: a) hidrógeno, b) alquilo, alquenilo o alquinilo, en donde dicho alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por hidroxi, alcoxi, amino, alquilamino, dialquilamino, heterociclilo, acilamino, alquilsulfonilamino y heterociclilcarbonilamino; y c) arilo o arilo sustituido; R3 es seleccionado del grupo formado por: (a) un grupo bicíclico, tricíclico o pentacíclico seleccionado del grupo formado por el grupo de fórmulas (2) en donde el grupo bicíclico, tricíclico o pentacíclico es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por: (i) alquilo, alquenilo y alquinilo, en donde cada grupo alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por (alcoxicarbonil)aralquilcarbamoilo, (amino)(R5)acihidrazinilcarbonilo, (amino)(R5)aciloxicarboxi, (hidroxi)(carboalcoxi)alquilcarbamoilo, acilaminoalquilamino, aciloxi, aldehido, alquenoxi, alquenilamino, alquenilsulfonilamino, alcoxi, alcoxicarbonilo, alcoxicarbonilalquilamino, alcoxicarbonilamino, alcoxicarbonilaminoaciloxi, alcoxicarbonilaminoalquilamino, alquilamino, alquilaminoalquilamino, alquilcarbamoilo, alquilfosfono, alquilsulfonilamino, alquilsulfoniloxi, amino, aminoaciloxi, aminoalquilaralquilcarbamoilo, aminoalquilcarbamoilo, aminoalquilheterocicloalquilcarbamoilo, aminocicloalquilalquilcicloalquilcarbamoilo, aminocicloalquilcarbamoilo, aralcoxicarbonilo, aralcoxicarbonilamino, arilheterociclo, ariloxi, arilsulfonilamino, arilsulfoniloxi, carbamoilo, carbonilo, ciano, cianoalquilcarbamoilo, cicloalquilamino, dialquilamino, dialquilaminoalquilamino, dialquilaminoalquilcarbamoilo, dialquilfosfono, haloalquilsulfonilamino, halógeno, heterociclilo, heterociclilalquilamino, heterociclilcarbamoilo, hidroxi, hidroxialquilsulfonilamino, oximino, fosfato, fosfono, -R5 R5-alcoxi, R5-alquil(alquil)amino, R5-alquilalquilcarbamoilo, R5-alquilamino, R5-alquilcarbamoilo, R5-alquilsulfonilo, R5-alquilsulfonilamino, R5-alquiltio, R5-heterociclilcarbonilo, aralquilamino sustituido, arilcarboxialcoxicarbonilo sustituido, arilsulfonilaminoalquilamino sustituido, heteroarilsulfonilamino sustituido, heterociclo sustituido, heterociclilaminoalquilamino sustituido, heterociclilsulfonilamino sustituido, sulfoxiacilamino, tiocarbamoilo, trifluorometilo; y (ii) (alcoxicarbonil)aralquilcarbamoilo, (amino)(R5)acilhidrazinilcarbonilo, (amino)(R5)aciloxicarboxi, (hidroxi)(carboalcoxi)alquilcarbamoilo, acilaminoalquilamino, aciloxi, aldehído, alquenoxi, alquenilamino, alquenilsulfonilamino, alcoxi, alcoxicarbonilo, alcoxicarbonilalquilamino, alcoxicarbonilamino, alcoxicarbonilaminoaciloxi, alcoxicarbonilaminoalquilamino, alquilamino, alquilaminoalquilamino, alquilcarbamoilo, alquilfosfono, alquilsufonilamino, alquilsulfoniloxi, amino, aminoaciloxi, aminoalquilaralquilcarbamoilo, aminoalquilcarbamoilo, aminoalquilheterociclilalquilcarbamoilo, aminocicloalquilalquilcicloalquilcarbamoilo, aminocicloalquilcarbamoilo, aralcoxicarbonilo, aralcoxicarbonilamino, arilheterociclilo, ariloxi, arilsulfonilamino, arilsulfoniloxi, carbamoilo, carbonilo, ciano, cianoalquilcarbamoilo, cicloalquilamino, dialquilamino, dialquilaminoalquilamino, dialquilaminoalquilcarbamoilo, dialquilfosfono, haloalquilsulfonilamino, halógeno, heterociclilo, heterociclilalquilamino, heterociclilcarbamoilo, hidroxi, hidroxialquilsulfonilamino, oximino, fosfato, fósforo, -R5 R5-alcoxi, R5-alquil(alquil)amino, R5-alquilalquilcarbamoilo, R5-alquilamino, R5-alquilcarbamoilo, R5-alquilsulfonilo, R5-alquilsulfonilamino, R5-alquiltio, R5-heterociclilcarbonilo, aralquilamino sustituido, arilcarboxialcoxicarbonilo sustituido, arilsulfonilaminoalquilamino sustituido, heteroarilsulfonilamino sustituido, heterociclo sustituido, heterociclilaminoalquilamino sustituido, sulfoxiacilamino, tiocarbamoilo, trifluorometilo; R4 es seleccionado del grupo formado por hidrógeno, alquilo C1-4, (alquilo C1-4)-CO2H y fenilo, en donde los grupos alquilo C1-4, (alquilo C1-4)-CO2H y fenilo son o no sustituidos o funcionalizados con uno a tres sustituyentes seleccionados del grupo formado por halógeno, -OH, OMe,-NH2-NO2 bencilo y bencilo funcionalizado con uno a tres sustituyentes seleccionados del grupo formado por halógeno, -OH, OMe, -NH2 y -NO2, R5 es seleccionado del grupo formado por -(CR1R2)nCOOH, -C(CF3)2OH, -CONHNHSO2CF3, -CONHOR4, -CONHSO2R4, -CONHSO2NHR4, -C(OH)R4PO3H2, -NHCOCF3, -NHCONHSO2R4, -NHPO3H2, NHSO2R4, -NHSO2NHCOR4, -OPO3H2, -OSO3H, -PO(OH)R4, -PO3H2, -SO3H, -SO2NHR4, -SO3NHCOR4, -SO3NHCONHCO2R4 y los siguientes grupo de fórmulas (3); n= 0, 1, 2, o 3; A es seleccionado de grupo formado por -CH=CH, -(CH)m-(CH)m, CH=CH-CH2 y -CH2-CH=CH; m = 1 o 2; X es O o S; Z es seleccionado del grupo formado por una ligadura simple, -O-, (CH2)n-, -O(CH2)1-2-, CH2OCH2-, -(CH2)1-2O-, y R6 es seleccionado del grupo formado por hidrógeno, alquilo, acilo, alquilsulfonilo, aralquilo, aralquilo sustituido, alquilo sustituido, y heterociclilo; y R7 es seleccionado del grupo formado por: a) hidrógeno; b) alquilo, alquenilo con no menos de 3 carbonos, o alquinilo con no menos de 3 carbonos, en donde dicho alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por hidroxi, alcoxi, amino, alquilamino, dialquilamino, heterociclilo, acilamino, alquilsulfonilamino y heterociclilcarbonilamino; c) arilo o arilo sustituido; y d) alquilarilo o arilo sustituido con alquilo. La invención provee además una composición farmacéutica que incluye el compuesto antedicho y un proceso para prepararlo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25065800P | 2000-12-01 | 2000-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035400A1 true AR035400A1 (es) | 2004-05-26 |
Family
ID=22948640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105594A AR035400A1 (es) | 2000-12-01 | 2001-11-30 | Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo |
Country Status (33)
Country | Link |
---|---|
US (2) | US6605601B2 (es) |
EP (1) | EP1347981B1 (es) |
JP (2) | JP2004514723A (es) |
KR (1) | KR20040011439A (es) |
CN (1) | CN100497340C (es) |
AR (1) | AR035400A1 (es) |
AT (1) | ATE394402T1 (es) |
AU (2) | AU1997702A (es) |
BG (1) | BG107849A (es) |
BR (1) | BR0115833A (es) |
CA (1) | CA2430508C (es) |
CZ (1) | CZ20031513A3 (es) |
DE (1) | DE60133931D1 (es) |
EA (1) | EA009814B1 (es) |
EE (1) | EE200300260A (es) |
ES (1) | ES2305139T3 (es) |
GE (1) | GEP20094697B (es) |
HK (1) | HK1059927A1 (es) |
HU (1) | HUP0400530A3 (es) |
IL (1) | IL156046A0 (es) |
IS (1) | IS6821A (es) |
MX (1) | MXPA03004857A (es) |
MY (1) | MY127120A (es) |
NO (1) | NO20032483L (es) |
NZ (1) | NZ526511A (es) |
PL (1) | PL362642A1 (es) |
SK (1) | SK6552003A3 (es) |
TR (1) | TR200300766T2 (es) |
TW (1) | TWI293301B (es) |
UA (1) | UA75625C2 (es) |
WO (1) | WO2002044182A1 (es) |
YU (1) | YU42903A (es) |
ZA (2) | ZA200304067B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60018216T2 (de) * | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Kondensierte purinderivate |
EA009814B1 (ru) * | 2000-12-01 | 2008-04-28 | Байоджен Айдек Ма Инк. | Конденсированные производные пурина как антагонисты рецепторов аденозина а |
EP1601649A4 (en) * | 2003-02-19 | 2009-03-04 | Endacea Inc | A1-adenosine receptor antagonistic |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
JPWO2004096812A1 (ja) * | 2003-04-25 | 2006-07-13 | 協和醗酵工業株式会社 | 縮合ピリミジン誘導体 |
RU2367442C2 (ru) * | 2003-04-25 | 2009-09-20 | Новокардия, Инк. | Способ нормализации мочеиспускания при нарушении функции почек |
CA2528385C (en) * | 2003-06-06 | 2011-03-15 | Endacea, Inc. | A1 adenosine receptor antogonists |
US20080161327A1 (en) * | 2005-03-11 | 2008-07-03 | Aderis Pharmaceuticals, Inc. | Substituted 9-Alkyladenines and the Use Thereof |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
CN101420958A (zh) * | 2006-04-06 | 2009-04-29 | 挪瓦卡尔迪阿公司 | 共投与腺苷a1受体拮抗剂和抗惊厥药 |
EP2018380B1 (en) | 2006-05-19 | 2011-10-19 | Abbott Laboratories | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
JP2009540003A (ja) * | 2006-06-16 | 2009-11-19 | ノヴァカーディア,インク. | Aa1raの低頻度投与を含む腎機能の長期間にわたる改善 |
BRPI0713619A2 (pt) | 2006-06-23 | 2013-01-15 | Incyte Corp | composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto. |
WO2007150026A2 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2011063268A2 (en) * | 2009-11-19 | 2011-05-26 | Biogen Idec Ma Inc | Novel synthetic methods |
US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
CN111770926B (zh) * | 2018-01-04 | 2023-07-21 | 因佩蒂斯生物科学有限公司 | 三环化合物、组合物及其医药应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06102662B2 (ja) | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
DE69033614T2 (de) * | 1989-10-20 | 2001-04-19 | Kyowa Hakko Kogyo Kk | Kondensierte Purinderivate |
SG52496A1 (en) | 1991-09-23 | 1998-09-28 | Univ Florida State | Preparation of substituted isoserine esters using metal alkoxides and beta-lactams |
AU4471297A (en) * | 1996-10-07 | 1998-05-05 | Kyowa Hakko Kogyo Co. Ltd. | Fused purine derivatives |
AU740770B2 (en) * | 1997-06-18 | 2001-11-15 | Aderis Pharmaceuticals, Inc. | Compositions and methods for preventing restenosis following revascularization procedures |
ES2284256T3 (es) * | 1998-07-02 | 2007-11-01 | Kyowa Hakko Kogyo Co., Ltd. | Medicamentos para la diabetes. |
DE60018216T2 (de) * | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Kondensierte purinderivate |
EA009814B1 (ru) * | 2000-12-01 | 2008-04-28 | Байоджен Айдек Ма Инк. | Конденсированные производные пурина как антагонисты рецепторов аденозина а |
-
2001
- 2001-11-30 EA EA200300629A patent/EA009814B1/ru not_active IP Right Cessation
- 2001-11-30 CZ CZ20031513A patent/CZ20031513A3/cs unknown
- 2001-11-30 US US09/997,740 patent/US6605601B2/en not_active Expired - Fee Related
- 2001-11-30 SK SK655-2003A patent/SK6552003A3/sk not_active Application Discontinuation
- 2001-11-30 EE EEP200300260A patent/EE200300260A/xx unknown
- 2001-11-30 UA UA2003066041A patent/UA75625C2/uk unknown
- 2001-11-30 TR TR2003/00766T patent/TR200300766T2/xx unknown
- 2001-11-30 WO PCT/US2001/044991 patent/WO2002044182A1/en active IP Right Grant
- 2001-11-30 MX MXPA03004857A patent/MXPA03004857A/es active IP Right Grant
- 2001-11-30 ES ES01998550T patent/ES2305139T3/es not_active Expired - Lifetime
- 2001-11-30 CN CNB018208711A patent/CN100497340C/zh not_active Expired - Fee Related
- 2001-11-30 TW TW090129678A patent/TWI293301B/zh active
- 2001-11-30 NZ NZ526511A patent/NZ526511A/en unknown
- 2001-11-30 AU AU1997702A patent/AU1997702A/xx active Pending
- 2001-11-30 KR KR10-2003-7007322A patent/KR20040011439A/ko active IP Right Grant
- 2001-11-30 AT AT01998550T patent/ATE394402T1/de not_active IP Right Cessation
- 2001-11-30 AU AU2002219977A patent/AU2002219977B2/en not_active Ceased
- 2001-11-30 PL PL01362642A patent/PL362642A1/xx not_active Application Discontinuation
- 2001-11-30 GE GEAP20017016A patent/GEP20094697B/en unknown
- 2001-11-30 AR ARP010105594A patent/AR035400A1/es unknown
- 2001-11-30 CA CA2430508A patent/CA2430508C/en not_active Expired - Fee Related
- 2001-11-30 IL IL15604601A patent/IL156046A0/xx unknown
- 2001-11-30 HU HU0400530A patent/HUP0400530A3/hu unknown
- 2001-11-30 JP JP2002546552A patent/JP2004514723A/ja active Pending
- 2001-11-30 DE DE60133931T patent/DE60133931D1/de not_active Expired - Lifetime
- 2001-11-30 YU YU42903A patent/YU42903A/sh unknown
- 2001-11-30 EP EP01998550A patent/EP1347981B1/en not_active Expired - Lifetime
- 2001-11-30 MY MYPI20015481A patent/MY127120A/en unknown
- 2001-11-30 BR BR0115833-3A patent/BR0115833A/pt not_active Application Discontinuation
-
2003
- 2003-05-20 IS IS6821A patent/IS6821A/is unknown
- 2003-05-26 ZA ZA200304067A patent/ZA200304067B/en unknown
- 2003-05-27 US US10/446,573 patent/US7022686B2/en not_active Expired - Fee Related
- 2003-05-27 BG BG107849A patent/BG107849A/bg unknown
- 2003-06-02 NO NO20032483A patent/NO20032483L/no not_active Application Discontinuation
-
2004
- 2004-02-27 HK HK04101469.6A patent/HK1059927A1/xx not_active IP Right Cessation
- 2004-10-28 ZA ZA200408755A patent/ZA200408755B/xx unknown
-
2009
- 2009-12-07 JP JP2009278047A patent/JP2010053148A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035400A1 (es) | Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo | |
IL256375A (en) | New histological histories, process for their preparation and pharmaceutical preparations containing them | |
HRP20200107T1 (hr) | Novi derivati hidroksiestera, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
BRPI0512690A (pt) | análogos de fosfonato de compostos inibidores de hiv | |
RU2014151850A (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
WO2009093209A3 (ru) | 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
DE602004003506D1 (de) | Perfluorpolyetheramidgebundene phosphonate, phosphate und derivate davon | |
NO20055590L (no) | Kinaseinhiberende fosfonatanaloger | |
AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
EA201390022A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
CL2004000965A1 (es) | Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com | |
SG178902A1 (en) | (thio)morpholine derivatives as s1p modulators | |
NO20004295L (no) | Nye pyridinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
AR040724A1 (es) | Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten | |
DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
PE20080534A1 (es) | Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr | |
KR900018031A (ko) | 아릴술폰아미드, 이를 함유한 약제학적 조성물 및 이들의 제조방법 | |
BR0213359A (pt) | Aralquiltetrahidropiridinas, sua preparação e composições farmacêuticas contendo as mesmas | |
AR125138A1 (es) | Nuevos derivados de 5,6,7,8-tetrahidropirido[4,3:4,5]tieno[2,3-d]pirimidin-4(3h)-ona como ligandos de sigma | |
AR047182A1 (es) | Derivados de 6-4{4-[1h- indol-2- sulfonil)-piperazin-1-carbonil-fenil]}piridazin-3-ona | |
DE3370619D1 (de) | Indole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |